BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Invited to Present at Prestigious LD 500 Virtual Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it joins the lineup of presenters at this year’s LD 500 Virtual Investor Conference. The annual LD Conference spotlights some of the most prominent companies in the micro-cap world, and also includes interviews and keynotes with small-cap leaders. GNPX chairman and CEO Rodney Varner will provde a company overview as well as updates on Genprex’s lead drug candidate, GPX-001, which recently received fast track designation from the U.S. Food and Drug Administration for use in combination with AstraZeneca’s Tagrisso(R) for treatment of late-stage lung cancer with EGFR mutations; the presentation will also include a summary of the company’s preclinical diabetes gene-therapy candidate designed to treat, and perhaps cure, type 1 and type 2 diabetes. Held online for the first time, the elite conference is scheduled for Sept. 1–4; Chalmers’s presentation is slated for 2 p.m. EST on Tuesday, Sept. 1. More information, including how to register, is available at https://ld500.ldmicro.com.

To view the full press release, visit http://ibn.fm/ZMAeb

About Genprex Inc.

Genprex is a clinical-stage, gene-therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes that currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “GPX-001” (“quaratusugene ozeplasmid”), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork